

# MACITENTAN (OPSUMIT®)

## EXPANDING CLINICAL UTILITY AND CHARACTERIZE MACITENTAN IN NEW PAH PATIENT POPULATIONS

- Maurice Beghetti, Rolf M.F. Berger.  
The challenges in paediatric pulmonary arterial hypertension  
European Respiratory Review 2014 23: 498-504;
- Gatzoulis MA, Beghetti M, Landzberg MJ, Galiè N.  
Pulmonary arterial hypertension associated with congenital heart disease: recent advances and future directions.  
Int J Cardiol 2014;177:340-7.
- Gatzoulis MA, Beghetti M, Berger RMF, Efficace M, Papadakis K, Galiè N, Landzberg M.  
A multi-centre randomised controlled trial of macitentan for the treatment of patients with Eisenmenger's syndrome: the MAESTRO study design and rationale. Euro GUCH (2015) Annual Meeting involving of the ESC Working Group on Grown-Up Congenital Heart Disease (GUCH)
- Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger R, Lauer A, Chiossi E, Landzberg M.  
Bosentan Therapy in Patients With Eisenmenger Syndrome. A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study.  
Circulation 2006;114:48-54


## STAY COMMITTED TO POST-LAUNCH CHARACTERIZATION AND SAFETY ACTIVITIES

- Kim NH, Chin K, Muros-Le Rouzic E, Brand M, Selej M, Channick RN, McLaughlin VV.  
OPsumit® USers Registry (OPUS): Insights into the safety and tolerability of Opsumit®.  
Am J Respir Crit Care Med. 2016;193(Meeting abstracts):A7396.
- McCollister D, Shaffer S, Badesch DB, et al.  
Development of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT®) questionnaire: a new patient-reported outcome instrument for PAH.  
Respir Res. 2016;17(1):72.
- Frantz R, Channick R, Chin K, Fischer A, Gomberg-Maitland M, Kleinman L, Miller C, Hunsche E, Zamanian R, Zastrow M, Badesch D.  
Psychometric validation of the Pulmonary Arterial Hypertension Symptoms and Impact (PAH-SYMPACT®) Questionnaire: Results from the SYMPHONY study.  
CHEST. 2016;150(4\_S):1160A.
- Chin K, Channick R, Fischer A, Frantz R, Gomberg-Maitland M, Kleinman L, Miller C, Hunsche E, Zamanian R, Badesch D.  
Item performance of the Pulmonary Arterial Hypertension Symptoms and Impact (PAH-SYMPACT®) questionnaire: results from the SYMPHONY study with macitentan  
[Presented at ERS International Congress 2016, London, UK, September 3-7, 2016].  
Eur Respir J. 2016;48(Suppl):in press

- Savale L, Magnier R, Le Pavec J, Jaïs X, Montani D, O'Callaghan DS, Humbert M, Dingemans J, Simonneau G, Sitbon O. Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. *Eur Respir J.* 2013 Jan;41(1):96-103.
- Medarov B, Chopra A, Judson MA. Clinical aspects of portopulmonary hypertension. *Respir Med.* 2014 Jul;108(7):943-54.
- Vonk Noordegraaf A, Galiè N. The role of the right ventricle in pulmonary arterial hypertension. *Eur Respir Rev.* 2011 Dec;20(122):243-53.
- Vonk-Noordegraaf A1, Souza R. Cardiac magnetic resonance imaging: what can it add to our knowledge of the right ventricle in pulmonary arterial hypertension? *Am J Cardiol.* 2012;110(6 Suppl):25S-31S.

## EXPANDING THE CLINICAL UTILITY OF MACITENTAN TO NEW CV INDICATIONS BEYOND PAH


- Marius M. Hoeper. Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension *European Respiratory Review* 2015 24: 272-282;
- Gewillig M, Goldberg DJ. Failure of the fontan circulation. *Heart Fail Clin.* 2014 Jan;10(1):105-16
- Park M, Ewald G, Franco V, Garcia-Ferrer J, Hage A, Horn E, Mandras S, Mathier M, Rame E, Selej M, Wang I-W, Frantz R. SOPRANO: Study of Macitentan in Patients with Pulmonary Hypertension (PH) Post-Left Ventricular Assist Device (LVAD) Implantation. *Journal of Cardiac Failure* 2016. 22, Issue 8, Supplement, Page S14
- Vachieri JL, Adir Y, Barbera JA et al. Pulmonary hypertension due to left heart diseases. *Journal of the American College of Cardiology* 2013;62:D100-8.
- Galiè N, Humbert M, Vachieri JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Respir J.* 2015 Oct;46(4):903-75.



# ACT-132577: ACTELION'S NEW ENDOTHELIN RECEPTOR ANTAGONIST

## FURTHER UTILIZE THE ENDOTHELIN PATHWAY, BUILDING ON OUR ERA EXPERTISE

- Vemulpalli S, Ard J, Backris GL et al. Proceedings from Duke Resistant Hypertension Think tank.  
Am Heart J 2014;167:775-88.e1.
- Judd E and Calhoun D. Apparent and true resistant hypertension: definition: prevalence and outcomes.  
J Human hypertension 2014;; 28(8):463-8.



# SELEXIPAG (UPTRAVI®)

## EXPANDING THE CLINICAL UTILITY OF SELEXIPAG

- Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV; Selexipag for the Treatment of Pulmonary Arterial Hypertension. *N Engl J Med*. 2015 Dec 24;373(26):2522-33
- Frost A, Benza RL, Farber H, Kim NH, Hartline B, Pfister T, Shiraga Y, McLaughlin V. TRANSIT 1: Evaluation of transition from inhaled treprostinil to oral selexipag. *Am J Respir Crit Care Med* 2016;193:A3977.
- Sitbon O, Jays X, Savale L, Cottin V, Bergot E, Macari EA, Bouvaist H, Dauphin C, Picard F, Bulifon S, Montani D, Humbert M, Simonneau G. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. *Eur Respir J* 2014; 43: 1691-1697.

